Skip to content

Viridian Therapeutics, Inc. VRDN Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
-$394K+90.4%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$862K-76.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1M-50.0%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$1.29M-58.7%
PVL
Palvella TherapeuticsPVLA
Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Revenue$141.0K+95.8%
Operating income-$116.2M-23.8%
Net income-$104.9M-20.7%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$176.3M+51.7%
Total debt$36.8M+59.4%
Total equity$636.0M+5.2%
Total assets$789.0M+19.4%

Cash flow

See full
Operating cash flow-$119.7M-29.1%
CapEx$23.0K-73.3%
Free cash flow-$119.7M-29.0%

Valuation

See full
Market cap$1.91B+82.0%
Enterprise value$1.77B+85.0%
P/S26.9×-3,445×

Profitability

See full
Gross margin36.3%
Operating margin-543.9%-271pp
Net margin-508.5%-254pp
FCF margin-428.4%-214pp

Returns & leverage

See full
Return on equity-58.1%+7.9pp
Debt / equity0.1×0.0×
Current ratio15.1×-4.3×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viridian Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viridian Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
Viridian Therapeutics, Inc. (VRDN) reported accretion (amortization) of discounts and premiums, investments of $1.86M in Q1 2026.
How has Viridian Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
Viridian Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 20.0% year-over-year, from $2.32M to $1.86M.
What is the long-term trend for Viridian Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 62.7% compound annual growth rate (CAGR), from -$965K to $6.76M.
What does accretion (amortization) of discounts and premiums, investments mean?
This represents the non-cash adjustment to interest income or expense resulting from the amortization of premiums or accretion of discounts on debt securities held as investments. It reflects the gradual adjustment of the carrying value of investment securities toward their face value over time. This metric is essential for reconciling net income to cash flow from operations by removing non-cash accounting impacts.